Bepirovirsen

Chronic hepatitis B · Adults with chronic hepatitis B

GSK · GSK plc

Regulatory designations

Full timeline

8 milestones

FDA approved Hibsago (bepirovirsen)

FDA approved Hibsago in combination with existing antiviral therapy for certain adults without cirrhosis who have chronic hepatitis B, have received antiviral therapy for at least six months, have suppressed HBV DNA, and have HBsAg levels of 3,000 IU/mL or less.

FDA — Hibsago approval announcement↗

FDA decision expected

FDA assigned an October 26, 2026 PDUFA goal date to the bepirovirsen NDA.

GSK — NDA acceptance and PDUFA date↗

Detailed Phase 3 B-Well results were reported

Across B-Well 1 and B-Well 2, 19% of qualifying participants achieved functional cure at week 72 with bepirovirsen plus standard of care versus 0% with placebo plus standard of care.

GSK — Detailed B-Well 1 and B-Well 2 results↗

FDA accepted the NDA with Priority Review

FDA accepted the application, granted Breakthrough Therapy designation and established the October goal date.

GSK — NDA acceptance and regulatory designations↗

Related News

Information for research purposes only · Dates can change · Last updated Oct 30, 2026